SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

TITAN BIOTECH

BSE: 524717 09 Sep 2025
Commodities
₹ 687.5
Titan Bio-Tech Ltd. specializes in Specialty Chemicals within the Commodities sector.

TITAN BIOTECH - Share Price & Details

Market Cap
₹547.0
High /Low
1,018 / 374.0
Stock P/E
24.9
Book Value
₹186.0
Dividend Yield
0.28
ROCE
16.9
ROE
₹15.0
Face Value
10.0
PEG Ratio
-108.0
EVEBITDA
₹18.2
Debt
2.80
CMP / FCF
51.5
Debt to equity
₹0.02
NP Ann
21.5
High price all time
1,018
Piotroski score
₹5.0
Graham Number
333.0
No. Eq. Shares
0.83
Net CF
₹2.29
Net profit
22.0
Price to book value
3.58
Interest Coverage
₹36.7
Low price all time
8.57
Industry PE
32.5
Reserves
₹145
Free Cash Flow
₹11.6

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
SOUTHERN GAS LTD.NANANANA0.060.03
INDO GULF INDUSTRIES LTD.NANANANA0
TITAN BIOTECH LTD.NANANANA547.024.9
SHREE RAMA NEWSPRINT LTD.101.44-102.7891.73-0.55539
ARIES AGRO LTD.1562.1691.71541.777.0553514.6

Peer Comparison Chart


About TITAN BIOTECH

Titan Bio-Tech Ltd., with Security Code 524717, is a leading player in the Specialty Chemicals industry, categorized under the Commodities sector, offering Equity instruments.


Latest News

$18M Financing: Purple Biotech Secures $6M Public Offering Plus $12M in Short-Term Warrant Potential

(06 Sep 2025)
Clinical-stage biotech Purple Biotech (NASDAQ: PPBT) closes offering of 6M ADSs at $1.00/share with warrants. Proceeds to advance oncology...
Read more →

$18M Financing Deal: Purple Biotech Prices Public Offering with $1.00 Warrants for Cancer Drug Development

(04 Sep 2025)
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies for tumor treatment, has announced the...
Read more →

26,000 Human Transcriptomes: Purple Biotech's Novel Cancer Drug Shows Promise in Resistant Tumors

(04 Sep 2025)
Mt. Sinai study demonstrates Purple Biotech's tri-specific antibody IM1240 induces tumor cell death in resistant head & neck cancer.
Read more →

Breakthrough 1-5pM Efficacy: Purple Biotech's Novel Triple-Action Cancer Antibody Shows Promise in TNBC

(04 Sep 2025)
Purple Biotech's IM1305 tri-specific antibody demonstrates tumor regression in TNBC with EC50 of 1-5pM. Platform targets TROP2 across breast...
Read more →

Clinical-Stage Cancer Drug Developer Purple Biotech to Present at Major Healthcare Conference

(27 Aug 2025)
Purple Biotech CEO Gil Efron to participate in fireside chat and 1x1 meetings at H.C. Wainwright Global Investment Conference on Sept 10,...
Read more →

Breakthrough: Taiwan's First FDA Phase 3 Botanical Drug BOTRESO Shows Promise in $9.8B BPH Market

(22 Aug 2025)
Jyong Biotech (NASDAQ:MENS) presented clinical trial results at the 22nd Urological Association of Asia Congress for two key drug candidates...
Read more →

Company Updates